These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16446329)

  • 1. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
    Verheijen RH; Massuger LF; Benigno BB; Epenetos AA; Lopes A; Soper JT; Markowska J; Vyzula R; Jobling T; Stamp G; Spiegel G; Thurston D; Falke T; Lambert J; Seiden MV
    J Clin Oncol; 2006 Feb; 24(4):571-8. PubMed ID: 16446329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival.
    Oei AL; Verheijen RH; Seiden MV; Benigno BB; Lopes A; Soper JT; Epenetos AA; Massuger LF
    Int J Cancer; 2007 Jun; 120(12):2710-4. PubMed ID: 17354223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consolidation for ovarian cancer in remission.
    Sabbatini P; Spriggs DR
    J Clin Oncol; 2006 Feb; 24(4):537-9. PubMed ID: 16446325
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
    Emons G; Ortmann O; Teichert HM; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
    Cancer; 1996 Oct; 78(7):1452-60. PubMed ID: 8839551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.
    Alberts DS; Hannigan EV; Liu PY; Jiang C; Wilczynski S; Copeland L; Markman M
    Gynecol Oncol; 2006 Jan; 100(1):133-8. PubMed ID: 16153694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance or consolidation therapy in advanced ovarian cancer.
    Pectasides D; Pectasides E
    Oncology; 2006; 70(5):315-24. PubMed ID: 17164587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radical peritonectomy in 37 patients with stage II and III ovarian cancer].
    Capretti PG; Zeppieri MC; Simonetti A; Rosato S; Lovotti D; Battaini A; Capretti G; Agnes Pradelli B
    Minerva Chir; 2004 Jun; 59(3):233-41. PubMed ID: 15252388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
    Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
    Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.
    Helm CW; Bristow RE; Kusamura S; Baratti D; Deraco M
    J Surg Oncol; 2008 Sep; 98(4):283-90. PubMed ID: 18726895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of epithelial ovarian cancer].
    Langmár Z; Csömör S
    Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.